文献速递慢性肾脏病水电解质与酸碱血液净化与透析

Etelcalcetide在日本血液透析继发性甲状旁腺功能亢进患者中的单次和多次给药多中心研究

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism.
PubMed 文献 · Kidney Int Rep · 2017-02-20

本研究为多中心、随机、双盲、安慰剂对照、平行组研究,在日本血液透析合并继发性甲状旁腺功能亢进患者中评估Etelcalcetide的药代动力学、药效学及安全性。单次给药(5、10、20 mg或安慰剂,每组6例,2:1随机)和多次给药(2.5或5 mg或安慰剂,每周3次共4周,每组11例,8:3随机)显示Etelcalcetide暴露呈剂量比例增加,单次给药30分钟内剂量依赖性降低血清iPTH,降幅1小时达平台并持续至8小时,第3天仍≥30%;多次给药效应在透析间期持续,血清cCa逐渐、剂量依赖性且持续降低。

要点

  • Etelcalcetide呈剂量比例暴露,血浆浓度透析后快速下降,透析间期稳定,第4周达稳态。
  • 单次给药30分钟内剂量依赖性降低iPTH,1小时达平台持续8小时,第3天降幅仍≥30%。
  • 多次给药(每周3次共4周)效应在透析间期持续,血清cCa逐渐、剂量依赖性持续降低。

核心结论

  • Etelcalcetide剂量依赖性降低血清iPTH和cCa,且效应在透析间期持续。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照、平行组研究,含单次给药和多次给药(每周3次共4周)两部分。
  • 单次给药3个队列(每组n=6),按2:1随机接受5、10或20 mg Etelcalcetide或安慰剂。
  • 多次给药2个队列(每组n=11),按8:3随机接受2.5或5 mg Etelcalcetide或安慰剂。
  • 主要入选标准:血液透析至少90天,血清iPTH≥300 pg/ml,血清白蛋白校正钙(cCa)≥9.0 mg/dl。

主要发现

  • 静脉给药后Etelcalcetide血浆浓度快速下降,给药后24小时至下次透析 generally 稳定,随后经透析降低。
  • Etelcalcetide暴露呈剂量比例增加,透析前血浆浓度在第4周接近稳态。
  • 单次给药30分钟内剂量依赖性降低血清iPTH,1小时达平台并持续至8小时,第3天降幅仍≥30%。
  • 多次给药末次注射(第27-29天)结果类似,效应在透析间期持续。
  • Etelcalcetide更逐渐但剂量依赖性且持续地降低血清cCa。

关键数值与推荐

  • 单次给药队列(n=6 each)随机2:1至5、10或20 mg Etelcalcetide或安慰剂。
  • 多次给药队列(n=11 each)随机8:3至2.5或5 mg Etelcalcetide或安慰剂,每周3次共4周。
  • 入选标准:血液透析≥90天,血清iPTH≥300 pg/ml,血清cCa≥9.0 mg/dl。

临床怎么用

  • 在日本血液透析合并继发性甲状旁腺功能亢进患者中,Etelcalcetide可剂量依赖性降低iPTH和cCa。
  • 给药后iPTH快速下降且效应维持至透析间期,cCa下降较 gradually 但持续,需监测相关指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The pharmacokinetics, pharmacodynamics, and safety and tolerability profile of etelcalcetide (ONO-5163/AMG 416), a novel, i.v., long-acting calcium-sensing receptor agonist, were studied in Japanese hemodialysis patients with secondary hyperparathyroidism. METHODS: This multicenter, randomized, double-blind, placebo-controlled, parallel-group study consisted of a single dose part and a multiple dose (3 times weekly for 4 weeks) part. Major inclusion criteria were hemodialysis for at least 90 days, serum intact parathyroid hormone (iPTH) ≥ 300 pg/ml, and serum albumin-corrected Ca (cCa) ≥ 9.0 mg/dl. There were 3 single-dose cohorts (n = 6 each) randomized 2:1 to 5, 10, or 20 mg etelcalcetide or placebo, and 2 multiple-dose cohorts (n = 11 each) randomized 8:3 to 2.5 or 5 mg etelcalcetide or placebo. RESULTS: Etelcalcetide plasma concentration decreased rapidly after i.v. administration, generally remained stable from 24 hours postdose to the next dialysis, and then decreased by dialysis. Etelcalcetide exposure increased dose proportionally. Etelcalcetide plasma predialysis concentration reached almost steady state at week 4. A single dose of etelcalcetide dose-dependently reduced serum iPTH in 30 minutes, and the reduction reached a plateau at 1 hour that lasted until 8 hours. The percent change from baseline serum iPTH thereafter showed a trend to gradually decrease; it was still -30% or greater on day 3. Similar results were obtained at the last injection (days 27-29) of the multiple dose. The effect of the multiple dose was sustained during the interdialytic period. Etelcalcetide decreased serum cCa in a more gradual but dose-dependent and sustained manner. DISCUSSION: Etelcalcetide dose-dependently reduced serum iPTH and serum cCa. Moreover, the effect was sustained in the interdialytic period.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Yokoyama K, Fukagawa M, Shigematsu T, et al. A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism. Kidney Int Rep. 2017. PMID: 29142982. doi:10.1016/j.ekir.2017.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。